Aliskiren (Tekturna, Rasilez) is the first of a new class of orally active antihypertensive drugs that works by inhibiting renin. A review of six large-scale clinical trials of aliskiren is being published in the May issue of the American Journal of Hypertension. The authors report that, because of reactive renin secretion, this drug has not been any more effective than those already widely available to control hypertension.
Renin inhibitors, for which aliskiren is a prototype, become the fourth class of drugs to lower blood pressure by blocking the renin-angiotensin system. Previously existing classes are beta blockers, converting enzyme inhibitors (CEIs) and angiotensin receptor blockers (ARBs). Many drugs in these classes have lost patent protection and are available as generics.
In analyzing clinical trials involving over 5000 hypertensive patients, aliskiren was not more effective as an antihypertensive agent than CEIs, ARBs or diuretics and it has a limited antihypertensive dose response curve. Although aliskiren lowered blood pressure to a greater extent when combined with a CEI or an ARB or a diuretic, blood pressure control was achieved by less than 50% of patients. Because aliskiren stimulates kidney renin secretion to a greater degree than do CEIs or ARBs, its antihypertensive capabilities can be counteracted by large reactive increases in renin secretion; this is particularly likely at higher dosage.
Writing in the article, Jean E. Sealey D.Sc. states, “Aliskiren’s pervasive stimulation of varying degrees of renin secretion could especially be a problem for those hypertensive patients who have hyper reactive renin systems such as patients with renovascular, advanced or malignant hypertension, all of whom were excluded from the trials. Their reactive renin responses might be so great as to induce a rise in blood pressure. Until the possibility of aliskiren inducing increases in blood pressure is eliminated it seems safer, and simple and wiser to stick to the less expensive, equally effective and widely available generic drugs for treating hypertensive disorders.”
The article is “Aliskiren, The First Renin Inhibitor for Treating Hypertension: Reactive Renin Secretion May Limit Its Effectiveness” by Jean E. Sealey DSc and John H. Laragh MD. It appears in the May 2007 issue of the American Journal of Hypertension, Volume 20/Issue 5, published by Elsevier.
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy